Senescence-regulatory factors as novel circulating biomarkers and therapeutic targets in regenerative medicine for osteoarthritis

Recent discoveries reveal that the chronic presence of senescent cells in osteoarticular tissues provides a focal point of disease development for osteoarthritis (OA). Nevertheless, senescence-regulatory factors associated with OA still need to be identified. Furthermore, few diagnostic-and prognostic-validated biochemical markers (biomarkers) are currently used in clinics to evaluate OA patients. In the future, alongside imaging and clinical examination, detecting senescence-regulatory biomarkers in patient fluids could become a prospective method for disease: diagnosis, monitoring, progression and prognosis following treatment. This review summarizes a group of circulating OA biomarkers recently linked to senescence onset. Remarkably, these factors identified in proteomics, metabolomic and microRNA studies could also have deleterious or protective roles in osteoarticular tissue homeostasis. In addition, we discuss their potentially innovative modulation in combination with senotherapeutic approaches, for long-lasting OA treatment.(c) 2023 Socie ' te ' franc, aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

Automated summary

Recent discoveries have shown that the presence of senescent cells in osteoarticular tissues plays a crucial role in the development of osteoarthritis (OA). However, the senescence-regulatory factors associated with OA still need to be identified. Additionally, there is a lack of diagnostic and prognostic biomarkers currently used in clinics to evaluate OA patients. In the future, detecting senescence-regulatory biomarkers in patient fluids, along with imaging and clinical examination, could become a promising method for diagnosing, monitoring, assessing progression, and predicting prognosis in OA patients.